Research ExplorerPublicationsIntrinsic BMP Antagonist Gremlin-1 as a Novel Circulating Ma...

Intrinsic BMP Antagonist Gremlin-1 as a Novel Circulating Marker in Pulmonary Arterial Hypertension

Standard

Intrinsic BMP Antagonist Gremlin-1 as a Novel Circulating Marker in Pulmonary Arterial Hypertension. / Wellbrock, Jasmin; Harbaum, Lars; Stamm, Hauke; Hennigs, Jan K; Schulz, Björn ; Klose, Hans; Bokemeyer, Carsten; Fiedler, Walter; Lüneburg, Nicole.

In: LUNG, 30.04.2015.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Wellbrock, J, Harbaum, L, Stamm, H, Hennigs, JK, Schulz, B, Klose, H, Bokemeyer, C, Fiedler, W & Lüneburg, N 2015, 'Intrinsic BMP Antagonist Gremlin-1 as a Novel Circulating Marker in Pulmonary Arterial Hypertension', LUNG. https://doi.org/10.1007/s00408-015-9735-5

APA

Wellbrock, J., Harbaum, L., Stamm, H., Hennigs, J. K., Schulz, B., Klose, H., Bokemeyer, C., Fiedler, W., & Lüneburg, N. (2015). Intrinsic BMP Antagonist Gremlin-1 as a Novel Circulating Marker in Pulmonary Arterial Hypertension. LUNG. https://doi.org/10.1007/s00408-015-9735-5

Vancouver

Wellbrock J, Harbaum L, Stamm H, Hennigs JK, Schulz B, Klose H et al. Intrinsic BMP Antagonist Gremlin-1 as a Novel Circulating Marker in Pulmonary Arterial Hypertension. LUNG. 2015 Apr 30. https://doi.org/10.1007/s00408-015-9735-5

Bibtex

@article{51294a328a434a429a8692d9bf1fc9e6,
title = "Intrinsic BMP Antagonist Gremlin-1 as a Novel Circulating Marker in Pulmonary Arterial Hypertension",
abstract = "Gremlin-1, an intrinsic antagonist of bone morphogenetic protein (BMP) signaling, has been implicated in the pathophysiology of pulmonary arterial hypertension (PAH). However, it is unknown whether gremlin-1 can be detected in the circulation of PAH patients and whether it is associated with patients' functional status and outcome. With a mean level of 242 ± 24 ng/ml, gremlin-1 levels of 31 PAH patients were significantly elevated compared to 151 ± 18 ng/ml in 15 age- and gender-matched healthy subject (p = 0.016). In PAH patients, increasing gremlin-1 levels correlated with N-terminal prohormone of brain natriuretic peptide levels (r = 0.608, p < 0.001) and inversely with the 6-minute walking distance (r = -0.412, p = 0.029). Furthermore, gremlin-1 significantly stratified survival in PAH patients (p = 0.015). Gremlin-1 may represent a new biomarker for PAH which can be linked directly to the underlying pathomechanism. Elevated levels of gremlin-1 are associated with patients' functional status and survival, thus gremlin-1 neutralization could represent a potential therapeutic strategy to increase BMPR2 signaling.",
author = "Jasmin Wellbrock and Lars Harbaum and Hauke Stamm and Hennigs, {Jan K} and Bj{\"o}rn Schulz and Hans Klose and Carsten Bokemeyer and Walter Fiedler and Nicole L{\"u}neburg",
year = "2015",
month = apr,
day = "30",
doi = "10.1007/s00408-015-9735-5",
language = "English",
journal = "LUNG",
issn = "0341-2040",
publisher = "Springer New York",

}

RIS

TY - JOUR

T1 - Intrinsic BMP Antagonist Gremlin-1 as a Novel Circulating Marker in Pulmonary Arterial Hypertension

AU - Wellbrock, Jasmin

AU - Harbaum, Lars

AU - Stamm, Hauke

AU - Hennigs, Jan K

AU - Schulz, Björn

AU - Klose, Hans

AU - Bokemeyer, Carsten

AU - Fiedler, Walter

AU - Lüneburg, Nicole

PY - 2015/4/30

Y1 - 2015/4/30

N2 - Gremlin-1, an intrinsic antagonist of bone morphogenetic protein (BMP) signaling, has been implicated in the pathophysiology of pulmonary arterial hypertension (PAH). However, it is unknown whether gremlin-1 can be detected in the circulation of PAH patients and whether it is associated with patients' functional status and outcome. With a mean level of 242 ± 24 ng/ml, gremlin-1 levels of 31 PAH patients were significantly elevated compared to 151 ± 18 ng/ml in 15 age- and gender-matched healthy subject (p = 0.016). In PAH patients, increasing gremlin-1 levels correlated with N-terminal prohormone of brain natriuretic peptide levels (r = 0.608, p < 0.001) and inversely with the 6-minute walking distance (r = -0.412, p = 0.029). Furthermore, gremlin-1 significantly stratified survival in PAH patients (p = 0.015). Gremlin-1 may represent a new biomarker for PAH which can be linked directly to the underlying pathomechanism. Elevated levels of gremlin-1 are associated with patients' functional status and survival, thus gremlin-1 neutralization could represent a potential therapeutic strategy to increase BMPR2 signaling.

AB - Gremlin-1, an intrinsic antagonist of bone morphogenetic protein (BMP) signaling, has been implicated in the pathophysiology of pulmonary arterial hypertension (PAH). However, it is unknown whether gremlin-1 can be detected in the circulation of PAH patients and whether it is associated with patients' functional status and outcome. With a mean level of 242 ± 24 ng/ml, gremlin-1 levels of 31 PAH patients were significantly elevated compared to 151 ± 18 ng/ml in 15 age- and gender-matched healthy subject (p = 0.016). In PAH patients, increasing gremlin-1 levels correlated with N-terminal prohormone of brain natriuretic peptide levels (r = 0.608, p < 0.001) and inversely with the 6-minute walking distance (r = -0.412, p = 0.029). Furthermore, gremlin-1 significantly stratified survival in PAH patients (p = 0.015). Gremlin-1 may represent a new biomarker for PAH which can be linked directly to the underlying pathomechanism. Elevated levels of gremlin-1 are associated with patients' functional status and survival, thus gremlin-1 neutralization could represent a potential therapeutic strategy to increase BMPR2 signaling.

U2 - 10.1007/s00408-015-9735-5

DO - 10.1007/s00408-015-9735-5

M3 - SCORING: Journal article

C2 - 25926293

JO - LUNG

JF - LUNG

SN - 0341-2040

ER -